哪里想瘦打哪里！FDA批准Kythera口服药物上市在即

你才双下巴，你全家都双下巴！所谓爱美之心人皆有之。如果说赘肉是每一个愿意保有完美身材的“妹纸”或“汉纸”的秦人，那么一个喜感十足的双下巴算是是这些人的生死无情了。每一分钟，为数众多都有人为自己的一张大饼脸而感到烦恼，虽然保有一个肉感十足的双下巴捏上去是挺有肉感的，但是还是有很多人的心理素质使其无法承受一个双下巴之重。您可千万别大笑，这甚至已经催生单单一个庞大的市场。根据American表皮外科手术协但会的调查研究显示，68%的American人对自己的双下巴表示了“厌倦”之情。而迫切需要，最近Kythera日本公司向FDA提交了其各种类型消灭双下巴的按摩注射基本型抗生素ATX-101。这种抗生素完成了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，算是是定点减肥。不要以为这种近乎天真的抗生素只是一个大笑话，在FDA的下属的表皮和诊疗抗生素专员但会的无记名投票之中，专家可是以17：0的超高票数相符赞同其并购。或许是因为这些专家之中也有很多饱受双下巴之苦吧。FDA也将计划于今年的5月13日之前对其作单单最后决定。如果一切顺利的话，Kythera日本公司计划于今年年末将该产品并购，分析人士预计这一抗生素的年销售额将至少3亿美元之多。随着按摩抗生素市场的愈发增大，Kythera日本公司算是是下了一步好棋。日本公司于上次以8400万美元的价格从其前伙伴拜耳手之中发还了这种抗生素的全部投票权。而Kythera日本公司也愿意以此为自始在按摩抗生素市场之中强攻拔寨。就在上个月，Kythera日本公司和Actelion日本公司达成协议商业价值2700万美元的合作伙伴协约，共同共同开发一种败北过的抗发炎抗生素，而这种抗生素被视为确实共同开发单单一种疗法神经性的抗生素。详细全名报导：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.